Stock Markets June 9, 2026 08:45 AM

Syntec Optics Wins $4.6M Order for Laser Blood-Test Cartridges, Shares Tick Higher

Order covers disposable point-of-care cartridges and optical reader subsystems with delivery scheduled by third quarter

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
OPTX

Syntec Optics Holdings Inc (NASDAQ:OPTX) said Tuesday it received a $4.6 million purchase order for the manufacture of laser blood-test cartridges and optical reader subsystems used in clinical laboratories and hospitals. Shares rose 4.3% in premarket trading. The order supports continued production of disposable point-of-care cartridges that measure hemoglobin, electrolytes, and metabolites, with partial shipments already made and final delivery planned by the third quarter.

Syntec Optics Wins $4.6M Order for Laser Blood-Test Cartridges, Shares Tick Higher
OPTX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Syntec Optics secured a $4.6 million purchase order for laser blood-test cartridges and optical reader subsystems.
  • The company reported a 4.3% rise in premarket shares following the announcement, reflecting market reaction to the order.
  • Approximately $500,000 of product has been shipped and full delivery is expected by the third quarter.

Syntec Optics Holdings Inc (NASDAQ:OPTX) reported a new $4.6 million purchase order for manufacturing laser blood-test cartridges and optical reader subsystems that are used in clinical laboratories and hospitals around the world. The company said the announcement coincided with a 4.3% rise in its shares during premarket trading on Tuesday.

The order is for continued production of disposable point-of-care cartridges designed to measure hemoglobin, electrolytes, and metabolites in clinical settings. These devices are employed across hospital networks and trauma centers, where deployments typically include multiple units operating in parallel in areas such as Intensive Care Units, Neonatal Intensive Care Units, operating rooms, and emergency departments.

Syntec Optics highlighted the speed advantage of the blood gas analyzers that form part of the product family. The analyzers provide critical oxygen, carbon dioxide, and clotting risk measurements in approximately one minute, a marked difference from the hours-long turnaround associated with traditional central laboratories. In intensive care, arterial blood gases are typically checked two to three times per day to support management of mechanical ventilation and to monitor metabolic stability.

Company executives signaled continuity between the firm’s expanding manufacturing work in space and defense sectors and its biomedical product lines. Chief Financial Officer Dean Rudy noted that while the company is advancing production capabilities for aerospace and defense applications, the biomedical business continues to generate stable, diversified, recurring revenue from products with long life cycles.

Operationally, Syntec has already shipped roughly $500,000 in goods toward this order, according to Director of Operations Jen Gale, and the company plans to complete full delivery by the third quarter. Facilities that use these systems typically perform between 400 and 750 tests per month, with high-volume clinical units processing 15 to 40 patient samples in every 24-hour period.

The order underscores ongoing demand for rapid point-of-care testing in hospital environments, where fast turnaround on blood gas and related measurements can be critical to patient management. Syntec’s mix of recurring biomedical revenue alongside its space and defense manufacturing work was presented by management as a source of diversification for the company’s top line.


Summary

  • Syntec Optics received a $4.6 million purchase order for laser blood-test cartridges and optical reader subsystems.
  • Shares traded up 4.3% in premarket trading following the announcement.
  • Approximately $500,000 of the order has been shipped; full delivery is targeted by the third quarter.

Details

  • The cartridges test hemoglobin, electrolytes, and metabolites and are used across hospital networks and trauma centers.
  • Blood gas analyzers deliver oxygen, carbon dioxide, and clotting risk data in about one minute, compared with hours for central labs.
  • Typical usage ranges from 400 to 750 tests per month per hospital or department, with busy units processing 15 to 40 samples per 24 hours.

Risks

  • Partial shipments have been made but final delivery depends on successful completion of production and logistics by the third quarter - this affects medical devices and healthcare supply chains.
  • Ongoing reliance on recurring biomedical product revenue may be influenced by demand patterns in hospital networks and trauma centers - impacting healthcare equipment and medical device markets.
  • Manufacturing commitments in space and defense alongside biomedical production could create operational complexity that may affect production scheduling and working-capital dynamics.

More from Stock Markets

Judge Gives Preliminary OK to $38 Billion Visa and Mastercard Settlement Over Swipe Fees Jun 9, 2026 Apple Unveils Overhauled Siri, Positions Upgrade as Answer to AI Competition Jun 9, 2026 Nvidia’s RTX Spark Targets Developers and Creators as AI PC Demand Remains Unproven Jun 9, 2026 Parabilis Medicines IPO Poised to Price at or Above Top of Range Jun 9, 2026 July Calls Drive Volume as Duolingo Options Activity Surges Jun 9, 2026